medigraphic.com
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2026, Number 1

<< Back Next >>

Alerg Asma Inmunol Pediatr 2026; 35 (1)

Clinical and epidemiological profile of patients with chronic spontaneous urticaria from a Tertiary Care Hospital in Mexico City

Pérez CH, Azamar JAA, González LRH

Language: Spanish
References: 24
Page: 5-10
PDF size: 713.68 Kb.


ABSTRACT

Chronic spontaneous urticaria (CSU) represents one of the most complex and demanding conditions in Clinical Allergy and Immunology practice. Its global prevalence ranges from 1% to 5% in the general population; behind these figures lies a widely underestimated socioeconomic and quality-of-life impact. As s frequent cause of consultation in our unit, the objective of this study was to describe the clinical and epidemiological characteristics of patients diagnosed with CSU. An observational, descriptive, cross-sectional, and retrospective study was conducted from January to December 2024 at the Clinical Allergy and Immunology Service of the Regional Hospital «Gral. Ignacio Zaragoza», enrolling all patients aged from 18 to 70 years with a confirmed diagnosis of CSU. Our findings revealed a prevalence of 5.6% for chronic urticaria and 0.3% for CSU, 86.4% of the cohort were female and 13.6% male, mean age of 51.3 ± 9.4 years. Phenotypically, 50% of the patients presented wheals, 22.7% angioedema and 27.3% both. In terms of therapeutic management, all patients were under monoclonal antibody therapy; nevertheless, 40.9% required concomitant treatment with antihistamines. Disease control assessment via UCT demonstrated 40.9% of patients controlled. Regarding disease activity measured by UAS7, 18.2% showed absence of activity, 45.5% wellcontrolled disease, 31.8% mild activity, and 4.5% moderate activity. In the quality of life evaluation via CuQ2oL, 90.9% perceived low overall impairment, while 9.1% reported none. This study allows us to document chronic urticaria as a significant burden in specialized medical consultations, exhibiting a epidemiological behavior consistent with global reports.


REFERENCES

  1. Larenas-Linnemann D, Medina-Ávalos MA, Ortega-Martell JA et al. Guía Mexicana para el Diagnóstico y el tratamiento de la urticaria. Rev Alerg Mex. 2014; 61(Supl 2): S118-S193.

  2. Kolkhir P, Giménez-Arnau AM, Kulthanan K et al. Urticaria. Nat Rev Dis Primers. 2022; 8 (1): 61.

  3. Zuberbier T, Abdul LAH, Abuzakouk M et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022; 77 (3): 734-766.

  4. Kolkhir P, Altrichter S, Asero R et al. Autoimmune diseases are linked to type iib autoimmune chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2021; 13 (4): 545-559. doi: 10.4168/aair.2021.13.4.545.

  5. Bansal CJ, Bansal AS. Stress, pseudoallergens, autoimmunity, infection and inflammation in chronic spontaneous urticaria. Allergy Asthma Clin Immunol. 2019; 15: 56.

  6. O’Donnell BF. Urticaria: impacto en la calidad de vida y costo económico. En: Greaves M, editor. Urticaria Clínica. 2ª ed. Barcelona: Elsevier; 2021. p. 45-52.

  7. Arias-Cruz A, González-Díaz SN, Macías-Weinmann A, et al. Calidad de vida en urticaria crónica y su relación con el impacto económico y control de la enfermedad en pacientes atendidos en el Hospital Universitario de Monterrey, México. Rev Alerg Méx. 2018; 65 (3): 250-258.

  8. Delong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol. 2008; 144 (1): 35-39.

  9. Zazzali JL, Broder MS, Chang E, Chiu MW, Hogan DJ. Cost, utilization, and patterns of medication use associated with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012; 108 (2): 98-102.

  10. Sánchez-Borges M, Ansotegui IJ, Baiardini I et al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021; 14 (6): 100533.

  11. Sugrañes-Montalván A, Barreto-Suárez E, Nicolau-Pestana E, Quesada-Leyva L. Relación entre infección por Helicobacter pylori y urticaria crónica [Relation between Helicobacter pylori infection and chronic urticaria]. Rev Alerg Mex. 2017; 64 (4): 396-402.

  12. Shalom G, Magen E, Babaev M, et al. Chronic urticaria and the metabolic syndrome: a cross-sectional community-based study of 11 261 patients. J Eur Acad Dermatol Venereol. 2018; 32 (2): 276-281.

  13. Cardona-Hernández MÁ, Candelaria de la Cruz PL. Urticarias crónicas inducibles. Clasificación y características generales. Rev Cent Dermatol Pascua. 2022; 31 (1-2): 16-25.

  14. Khan DA, Kocatürk E, Bauer A, Aygoren-Pürsün E. What’s new in the treatment of urticaria and angioedema. J Allergy Clin Immunol Pract. 2021; 9 (6): 2170-2184.

  15. Metz M, Maurer M. Use of biologics in chronic spontaneous urticaria - beyond omalizumab therapy? Allergol Select. 2021; 5: 89-95.

  16. Zuberbier T, Asero R, Bindslev-Jensen C et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009; 64 (10): 1427-1443.

  17. Cardona R, Marín-Serrano MH. Instrumentos de evaluación de la calidad de vida en dermatología. Iatreia. 2013; 26 (4): 467-475.

  18. Maurer M, Ziegler S, Giménez-Arnau A, Marcelino J, Khan DA, Sussman G, et al. Omalizumab treatment patterns and disease burden in chronic spontaneous urticaria: 2-year results from the AWARE study. Allergy. 2019; 74 (12): 2408-2419.

  19. Oliver ET, Saini SS. Chronic spontaneous urticaria: etiology and pathogenesis. Immunol Allergy Clin North Am. 2024; 44 (3): 421-438.

  20. Gómez RM, Jares E, Borges MS et al. Latin American chronic urticaria registry (CUR) contribution to the understanding and knowledge of the disease in the region. World Allergy Organ J.2019; 12 (6): 100042.

  21. Ensina LF, Cusato-Ensina AP, Cardona R. Advances inthe pathogenesis representing definite outcomes in chronicurticaria. Curr Opin Allergy Clin Immunol. 2019; 19 (3): 193-197.

  22. Vena GA, Cassano N. The link between chronic spontaneousurticaria and metabolic syndrome. Eur Ann Allergy ClinImmunol. 2017; 49 (5): 208-212.

  23. Casale TB, Gimenez-Arnau AM, Bernstein JA et al. Omalizumabfor patients with chronic spontaneous urticaria: a narrativereview of current status. Dermatol Ther (Heidelb). 2023; 13(11): 2573-2588.

  24. Maurer M, Weller K, Bindslev-Jensen C et al. Unmet clinicalneeds in chronic spontaneous urticaria. A GA²LEN task forcereport. Allergy. 2011; 66 (3): 317-330.




2020     |     www.medigraphic.com